Share

March 2021; 8 (2) ArticleOpen Access

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab

Regina Berkovich, Aida Yakupova, Jonathan Eskenazi, Noel G. Carlson, Lawrence Steinman
First published February 15, 2021, DOI: https://doi.org/10.1212/NXI.0000000000000961
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
541

Share

Article Information

vol. 8 no. 2 e961
DOI: 
https://doi.org/10.1212/NXI.0000000000000961
PubMed: 
33589543
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 14, 2020
  • Accepted in final form December 8, 2020
  • First Published February 15, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Regina Berkovich, MD, PhD,
    2. Aida Yakupova, MD, PhD (aidayakupova{at}yandex.ru),
    3. Jonathan Eskenazi, MD (jeskena{at}hotmail.com),
    4. Noel G. Carlson, PhD (noel.carlson{at}va.gov) and
    5. Lawrence Steinman, MD (aidayakupova{at}yandex.ru)
  1. Regina Berkovich, MD, PhD,
    2. Scientific Advisory Boards:

    1. (1)MSAA (2)NMSS (3)Biogen (4)Genentech (5)Novartis (6) Sanofi (7)Bayer (8)Mallinckrodt (9)Alexion (10) Celgene

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel and Speaker honoraria received from Alexion, Bayer, Biogen, Celgene, Sanofi, Genentech, Mallinckrodt, Novartis,

    Editorial Boards:

    1. Journal of Medical Case Reports - Associate Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Regina Berkovich MD, PhD Inc (2018-present) USC Keck School of Medicine USC Neurology (2004-2018) Teaching faculty for USC+LAC (2006-present)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Alexion, Biogen, Celgene, Sanofi, Novartis, Mallinckrodt

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen Sanofi Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Aida Yakupova, MD, PhD (aidayakupova{at}yandex.ru),
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jonathan Eskenazi, MD (jeskena{at}hotmail.com),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Noel G. Carlson, PhD (noel.carlson{at}va.gov) and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. I am employed by the Department of Veterans Affairs and the University of Utah.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I have received research support from: Biogen and Astra Zeneca.

    Research Support, Government Entities:

    1. I have received funding from The Department of Veterans Affairs Merit Review.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Lawrence Steinman, MD (aidayakupova{at}yandex.ru)
    6. Scientific Advisory Boards:

    1. Novartis, Atreca, Bristol Myers Squibb, Gossamer, 180LS, TG Therapeutics, Atara Bio

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Novartis, Atara Bio

    Editorial Boards:

    1. MS Journal, Proceedings National Academy of Sciences

    Patents:

    1. I have a patent pending on cytokines and type 1 interferons. I have multiple patents on antigen specific tolerance.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Commercial Novartis, Atreca, Tolerion, Teva, AbbVie, Bristol Myers Squibb, Gossamer, 180LS, TG Therapeutics, Atara Bio

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Atara Bio, Novartis

    Research Support, Government Entities:

    1. NIH 2U01AI101984-06 Cooperative Study Group for Autoimmune Disease Prevention (U01)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Stock options and board membership in Atreca Board of Directors BioAtla

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Tolerion Stock/Stock Options, Medical Equipment & Materials: Tolerion, Atreca, Adaptive

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the LA County and University of Southern California General Hospital and Clinic (R.B.), Los Angeles; Kazan State Medical University (A.Y.), Russia; UCLA (J.E.), Los Angeles, CA; GRECC, VA Salt Lake, University of Utah (N.C.), Salt Lake City; and Stanford University (L.S.), Palo Alto, CA.
  1. Correspondence
    Dr. Berkovich reginaberkovichmd{at}gmail.com

Article usage

Article usage: February 2021 to October 2023

AbstractFullPdfSource
Feb 2021840644Highwire
Mar 2021816439Highwire
Apr 202146327Highwire
May 202115321Highwire
Jun 202125927Highwire
Jul 202136320Highwire
Aug 20212746Highwire
Sep 202165013Highwire
Oct 202159334Highwire
Nov 202115431Highwire
Dec 20212478Highwire
Jan 202218928Highwire
Feb 2022214911Highwire
Mar 202237719Highwire
Apr 20220697Highwire
May 202217217Highwire
Jun 20221946Highwire
Jul 202216512Highwire
Aug 202221386Highwire
Sep 2022310815Highwire
Oct 202229810Highwire
Nov 2022710922Highwire
Dec 202229713Highwire
Jan 202339212Highwire
Feb 2023310516Highwire
Mar 20230705Highwire
Apr 202324713Highwire
May 20233497Highwire
Jun 202317611Highwire
Jul 202316018Highwire
Aug 202335812Highwire
Sep 20231878Highwire
Oct 20233293Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles